These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 11600828)

  • 1. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
    Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
    AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy.
    Estrada V; Serrano-Ríos M; Martínez Larrad MT; Villar NG; González López A; Téllez MJ; Fernández C
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):32-40. PubMed ID: 11782587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
    Hadigan C; Corcoran C; Stanley T; Piecuch S; Klibanski A; Grinspoon S
    J Clin Endocrinol Metab; 2000 Jan; 85(1):35-41. PubMed ID: 10634360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.
    Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP
    J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy.
    Huang JS; Rietschel P; Hadigan CM; Rosenthal DI; Grinspoon S
    AIDS; 2001 May; 15(8):975-82. PubMed ID: 11399979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
    AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.
    Kosmiski L; Kuritzkes D; Hamilton J; Sharp T; Lichtenstien K; Hill J; Eckel R
    HIV Med; 2003 Jul; 4(3):235-40. PubMed ID: 12859322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipocyte-derived hormone levels in HIV lipodystrophy.
    Kosmiski L; Kuritzkes D; Lichtenstein K; Eckel R
    Antivir Ther; 2003 Feb; 8(1):9-15. PubMed ID: 12713059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
    Gan SK; Samaras K; Thompson CH; Kraegen EW; Carr A; Cooper DA; Chisholm DJ
    Diabetes; 2002 Nov; 51(11):3163-9. PubMed ID: 12401706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Sharp TA; Hamilton JT; Lichtenstein KA; Mosca CL; Grunwald GK; Eckel RH; Hill JO
    Metabolism; 2003 May; 52(5):620-5. PubMed ID: 12759894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
    Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A
    Curr HIV Res; 2009 Jul; 7(4):454-61. PubMed ID: 19601783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.
    van der Valk M; Bisschop PH; Romijn JA; Ackermans MT; Lange JM; Endert E; Reiss P; Sauerwein HP
    AIDS; 2001 Nov; 15(16):2093-100. PubMed ID: 11684928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
    Yanovski JA; Miller KD; Kino T; Friedman TC; Chrousos GP; Tsigos C; Falloon J
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1925-31. PubMed ID: 10372688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
    AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
    Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA;
    HIV Clin Trials; 2004; 5(4):192-200. PubMed ID: 15472793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.